NCT02874807View on ClinicalTrials.gov

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 5, 2016

Primary Completion Date

December 14, 2018

Study Completion Date

January 14, 2019

Conditions
SIADH
Interventions
DRUG

Empagliflozin

OTHER

Placebo

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT02874807 - Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study | Biotech Hunter | Biotech Hunter